By Colin Kellaher
Gilead Sciences on Monday said it named Merdad Parsey chief medical officer, effective Nov. 1.
The Foster City, Calif., biopharmaceutical company said Mr. Parsey is joining from Roche Holdings AG's (ROG.EB) Genentech Inc. unit, where he serves as senior vice president of early clinical development in the research and early development group.
Gilead in July said John McHutchison was stepping down as chief scientific officer and head of research and development. Mr. McHutchison was later named president and chief executive of clinical-stage biotechnology company Assembly Biosciences.
Gilead said Mr. Parsey, who will be responsible for the company's global clinical development and medical affairs organizations, will report directly to Chairman and Chief Executive Daniel O'Day under a new leadership structure, as will William Lee, who serves as executive vice president of research.
Write to Colin Kellaher at email@example.com